Vigil Neuroscience (NASDAQ:VIGL) Cut to Hold at Mizuho

Mizuho cut shares of Vigil Neuroscience (NASDAQ:VIGL - Free Report) from a strong-buy rating to a hold rating in a report issued on Friday morning,Zacks.com reports.

Other analysts have also recently issued reports about the stock. William Blair cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright decreased their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Friday, March 14th. JMP Securities reissued a "market perform" rating on shares of Vigil Neuroscience in a research note on Thursday, May 22nd. Citigroup cut Vigil Neuroscience to a "market perform" rating in a report on Thursday, May 22nd. Finally, Citizens Jmp downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Ten investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Vigil Neuroscience currently has an average rating of "Hold" and a consensus target price of $10.80.

Vigil Neuroscience Stock Up 0.1%

VIGL stock traded up $0.01 during mid-day trading on Friday, hitting $7.89. The company had a trading volume of 1,951,012 shares, compared to its average volume of 647,938. The company has a market capitalization of $368.24 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. Vigil Neuroscience has a 12-month low of $1.31 and a 12-month high of $7.95. The company has a 50-day moving average price of $2.43 and a 200 day moving average price of $2.35.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, analysts expect that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Trading of Vigil Neuroscience

Large investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC increased its holdings in Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after purchasing an additional 8,358 shares during the period. Northern Trust Corp grew its position in shares of Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock worth $110,000 after buying an additional 14,572 shares in the last quarter. Barclays PLC increased its stake in shares of Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares during the period. Two Sigma Investments LP raised its holdings in shares of Vigil Neuroscience by 44.0% in the fourth quarter. Two Sigma Investments LP now owns 136,920 shares of the company's stock valued at $233,000 after acquiring an additional 41,836 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Vigil Neuroscience in the fourth quarter worth about $83,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.